Baseline characteristics of all study patients
| All groups | SA (n = 21) | UA (n = 15) | MI (n = 18) | |
|---|---|---|---|---|
| Coronary risk factors were defined as described previously.18 | ||||
| *p<0.05 compared with MI group; †p<0.001 compared with SA group. | ||||
| ACE, angiotensin converting enzyme; MI, myocardial infarction; SA, stable angina pectoris; UA, unstable angina pectoris. | ||||
| Mean (SD) age (years) | 58.8 (2.3) | 58.6 (3.3 | 59.7 (3.0 | |
| Male | ||||
| Yes | n = 44 | 17 (39%) | 13 (30%) | 14 (32%) |
| No | n = 10 | 4 (40%) | 2 (20%) | 4 (40%) |
| Hypertension | ||||
| Yes | n = 14 | 3 (21%) | 5 (36%) | 6 (43%)) |
| No | n = 38 | 18 (47%) | 10 (26%) | 12 (32%) |
| Hypercholesterolaemia | ||||
| Yes | n = 16 | 6 (38%) | 3 (19%) | 7 (44%) |
| No | n = 38 | 15 (39%) | 12 (32%) | 11 (29%) |
| Family history | ||||
| Yes | n = 17 | 5 (29%) | 5 (29%) | 7 (41%) |
| No | n = 37 | 16 (43%) | 10 (27%) | 11 (30%) |
| Cigarette smoking | ||||
| Yes | n = 25 | 8 (32%) | 11 (44%) | 6 (24%) |
| No | n = 29 | 13 (45%) | 4 (14%) | 12 (41%) |
| Nitrate | ||||
| Yes | n = 32 | 19* (59%) | 10* (31%) | 3 (9%) |
| No | n = 22 | 2* (9%) | 5 (23%) | 15 (69%) |
| β Blocker | ||||
| Yes | n = 32 | 17* (53%) | 12* (38%) | 3 (9%) |
| No | n = 22 | 4 (18%) | 3* (14%) | 15 (69%) |
| Calcium antagonist | ||||
| Yes | n = 32 | 18* (56%) | 13* (41%) | 1 (3%) |
| No | n = 22 | 3* (14%) | 2* (9%) | 17 (77%) |
| Aspirin | ||||
| Yes | n = 42 | 19* (45%) | 13* (31%) | 10 (24%) |
| No | n = 12 | 2* (17%) | 2* (17%) | 8 (67%) |
| Statin | ||||
| Yes | n = 5 | 1 (20%) | 2 (40%) | 40% (2) |
| No | n = 49 | 20 (41%) | 13 (27%) | 16 (33%) |
| ACE inhibitors | ||||
| Yes | n = 7 | 3 (43%) | 2 (29%) | 2 (29%) |
| No | n = 47 | 18 (38%) | 28% (13) | 16 (34%) |
| Mean (SD) diameter stenosis (%) | 67.7 (11.7) | 71.4 (9.2)*† | 99.9 (0.2)† | |
| Mean (SD) reference diameter (mm) | 3.60 (0.73) | 3.77 (0.43) | 3.66 (0.63) | |
| Mean (SD) time interval between symptoms and atherectomy (days) | 130 (23) | 10.0 (2.86)*† | 0.13 (0.015)† | |